News Quantified

NVZMY – novonesis b unsp/adr (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Novozymes A/S (OTCMKTS: NVZMY) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.

Novozymes A/S (OTCMKTS: NVZMY) was downgraded by analysts at Citigroup Inc. from a "neutral" rating to a "sell" rating.

Novozymes A/S (OTCMKTS: NVZMY) was upgraded by analysts at Berenberg Bank to a "strong-buy" rating.

6.6%

BEAT

Top News Gainers

1/23 Q4/2019 12/31/2019 EPS 3.250 ZacksConsensus 0.440 ActVsEst 2.810 - Beat 6.5%

10/23 Novozymes CEO Expects Downturn In U.S. Bioethanol Market To Continue In Q4 [Reuters] 5.2%

3/25 NOVOZYMES A/S/S (OTCMKTS: NVZMY) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $60.00 price target on the stock. 4.4%

4/30 Q1/2020 3/31/2020 EPS 2.880 ZacksConsensus 0.440 ActVsEst 2.440 - Beat 3.2%

4/29 Q1/2020 3/31/2020 EPS 2.880 ZacksConsensus 0.440 ActVsEst 2.440 - Beat 3.1%

4/29 Q1/2020 3/31/2020 EPS 2.880 ZacksConsensus 0.440 ActVsEst 2.440 - Beat 2.5%

10/15 NOVOZYMES A/S/S (OTCMKTS: NVZMY) was upgraded by analysts at Zacks Investment Research from a "strong sell" rating to a "hold" rating. 2.1%

10/24 Q3/2019 9/30/2019 EPS 2.230 ZacksConsensus 0.430 ActVsEst 1.800 - Beat 1.8%

10/23 Q3/2019 9/30/2019 EPS 2.230 ZacksConsensus 0.430 ActVsEst 1.800 - Beat 1.8%

11/20 NOVOZYMES A/S/S (OTCMKTS: NVZMY) was upgraded by analysts at Citigroup Inc from a "neutral" rating to a "buy" rating. 1.6%

Top News Decliners

8/8 Q2/2019 6/30/2019 EPS 3.120 ZacksConsensus 0.530 ActVsEst 2.590 - Beat -5.0%

4/21 NOVOZYMES A/S/S (OTCMKTS: NVZMY) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $53.00 price target on the stock. -4.6%

8/9 Q2/2019 6/30/2019 EPS 3.120 ZacksConsensus 0.530 ActVsEst 2.590 - Beat -4.1%

3/14 NOVOZYMES A/S/S (OTCMKTS: NVZMY) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -3.6%

7/30 NOVOZYMES A/S/S (OTCMKTS: NVZMY) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -2.3%

3/31 NOVOZYMES A/S/S (OTCMKTS: NVZMY) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -1.8%

6/20 NOVOZYMES A/S/S (OTCMKTS: NVZMY) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -1.5%

1/24 Q4/2019 12/31/2019 EPS 3.250 ZacksConsensus 0.440 ActVsEst 2.810 - Beat -1.3%

4/1 NOVOZYMES A/S/S (OTCMKTS: NVZMY) was downgraded by analysts at Goldman Sachs Group Inc from a "buy" rating to a "sell" rating. -1.2%

11/7 2 Holdings to Reduce Based on Analyst Recommendations [Yahoo! Finance News] -1.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day